TNFRSF17 and plasma cell myeloma: Currently, there are several CAR-T therapies targeting CD19 for the treatment of B cell leukemia and lymphoma, and B cell maturation antigen (BCMA) for the treatment of multiple myeloma, at least 5 of which have received regulatory approval for commercial treatment in numerous countries as of mid-2023.